Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Acquired by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. raised its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,132 shares of the medical equipment provider’s stock after acquiring an additional 801 shares during the period. Atria Wealth Solutions Inc.’s holdings in Intuitive Surgical were worth $4,768,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Harvest Fund Management Co. Ltd lifted its stake in Intuitive Surgical by 49.1% during the 4th quarter. Harvest Fund Management Co. Ltd now owns 4,593 shares of the medical equipment provider’s stock valued at $1,544,000 after acquiring an additional 1,512 shares during the period. GAMMA Investing LLC acquired a new position in shares of Intuitive Surgical in the 4th quarter valued at $768,000. Linden Thomas Advisory Services LLC lifted its stake in shares of Intuitive Surgical by 9.6% in the 4th quarter. Linden Thomas Advisory Services LLC now owns 5,920 shares of the medical equipment provider’s stock valued at $1,997,000 after purchasing an additional 517 shares during the period. Parkside Financial Bank & Trust lifted its stake in shares of Intuitive Surgical by 6.3% in the 4th quarter. Parkside Financial Bank & Trust now owns 623 shares of the medical equipment provider’s stock valued at $210,000 after purchasing an additional 37 shares during the period. Finally, Marks Group Wealth Management Inc lifted its stake in shares of Intuitive Surgical by 1.3% in the 4th quarter. Marks Group Wealth Management Inc now owns 10,963 shares of the medical equipment provider’s stock valued at $3,698,000 after purchasing an additional 139 shares during the period. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Stock Up 0.6 %

Intuitive Surgical stock opened at $375.33 on Friday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The company has a fifty day simple moving average of $386.19 and a 200-day simple moving average of $345.95. The firm has a market capitalization of $133.13 billion, a price-to-earnings ratio of 67.75, a PEG ratio of 4.82 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The firm had revenue of $1.89 billion during the quarter, compared to analyst estimates of $1.87 billion. During the same quarter in the prior year, the firm posted $1.00 earnings per share. Intuitive Surgical’s quarterly revenue was up 11.5% on a year-over-year basis. On average, research analysts anticipate that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently issued reports on ISRG. Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Mizuho boosted their target price on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research note on Thursday, January 25th. Jefferies Financial Group boosted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research note on Friday, April 19th. Truist Financial upped their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 24th. Finally, Robert W. Baird reduced their price objective on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $396.17.

Insider Activity at Intuitive Surgical

In related news, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares of the company’s stock, valued at $736,800. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Intuitive Surgical news, EVP Robert Desantis sold 20,296 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at $2,168,656.60. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mark Brosius sold 196 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the transaction, the senior vice president now directly owns 1,842 shares of the company’s stock, valued at approximately $736,800. The disclosure for this sale can be found here. Over the last quarter, insiders sold 249,418 shares of company stock valued at $96,300,959. 0.90% of the stock is owned by company insiders.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.